--> --> -->

 
--------------------------------------------------------------------------------

                      SECURITIES AND EXCHANGE COMMISSION
                            Washington, D.C. 20549

                                ---------------

                                SCHEDULE 13E-4

                                ---------------

                         ISSUER TENDER OFFER STATEMENT
                     (Pursuant to Section 13(e)(1) of the
                       Securities Exchange Act of 1934)
                               (AMENDMENT NO. 2)

                                ---------------

                             ELI LILLY AND COMPANY
                               (Name of Issuer)


                             ELI LILLY AND COMPANY
                     (Name of Person(s) Filing Statement)

                             COMMON STOCK, without
                                   par value
                        (Title of Class of Securities)

                                  532457 10 8
                     (CUSIP Number of Class of Securities)

                                Rebecca O. Goss
                             ELI LILLY AND COMPANY
                            Lilly Corporate Center
                          Indianapolis, Indiana 46285
                                (317) 276-2000

                                   -Copy to-

                                Bernard E. Kury
                               Dewey Ballantine
                          1301 Avenue of the Americas
                         New York, New York 10019-6092
                                (212) 259-8000

          (Name, Address and Telephone Number of Person Authorized to
               Receive Notices and Communications on Behalf of
                          Person(s) Filing Statement)

                                August 21, 1995
                   (Date Tender Offer First Published, Sent
                         or Given to Security Holders)

--------------------------------------------------------------------------------

 
        This Amendment No. 2 amends and supplements the Issuer Tender Offer
Statement on Schedule 13E-4, dated August 21, 1995, as amended, of Eli Lilly and
Company, an Indiana corporation ("Lilly"), relating to the offer by Lilly to
exchange 3.49 shares of common stock, without par value ("Guidant Common
Stock"), of Guidant Corporation, an Indiana corporation ("Guidant"), of which
Lilly owns 80.2% of the issued and outstanding shares, for each share of common
stock of Lilly, without par value ("Lilly Common Stock"), upon the terms and
subject to the conditions set forth in the Offering Circular - Prospectus dated
August 21, 1995, as supplemented by an Offering Circular - Prospectus Supplement
dated September 6, 1995 (together, the "Offering Circular - Prospectus") and the
related Letter of Transmittal. Capitalized terms used but not defined herein
have the meanings ascribed to them in the Offering Circular - Prospectus.

Item 9.  Material to be Filed as Exhibits.

         (a)(13)  Press Release dated September 19, 1995.

         (a)(14)  Press Release dated September 19, 1995.

                                       2

 
                                   SIGNATURE

        After due inquiry and to the best of my knowledge and belief, I certify 
that the information set forth in this statement is true, complete and correct.

Dated: September 19, 1995

                                                ELI LILLY AND COMPANY


                                                By: /s/ Edwin W. Miller
                                                   -------------------------
                                                   Name:  Edwin W. Miller
                                                   Title: Vice President and 
                                                          Treasurer




                                       3

 
                                 EXHIBIT INDEX

Exhibit No.             Description                     Page No.
-----------             -----------                     --------

(a)(13)                 Press Release dated                5
                        September 19, 1995

(a)(14)                 Press Release dated                7
                        September 19, 1995

                                       4

 
                                                               EXHIBIT (a)(13)

        Lilly and Guidant Announce Completion of Guidant Exchange Offer

Eli Lilly and Company (NYSE: LLY) and Guidant Corporation (NYSE: GDT) announced 
today the successful completion of the Exchange Offer by which Lilly 
shareholders were given the opportunity to exchange some, all or none of their 
shares of Lilly Common Stock for Guidant Common Stock. The Exchange Offer, which
was oversubscribed, expired at midnight, New York City time, on Monday, Sept. 
18, 1995.

Based on a preliminary count by the exchange agent, approximately 47,378,800
shares of Lilly Common Stock were tendered for exchange, including approximately
882,124 shares held by odd-lot shareholders and 13,667,302 shares subject to
guarantees of delivery. In accordance with the terms of the Exchange Offer,
Lilly will accept 16,504,298 Lilly shares in exchange for the 57,600,000 shares
of Guidant Common Stock that it owns. Lilly will accept all shares tendered by
eligible odd-lot shareholders. All other shares are subject to exchange on a 
pro-rata basis. The preliminary proration factor is 35.5 percent, assuming all
shares subject to guarantees of delivery are delivered in accordance with the
terms of the Exchange Offer. The final proration factor will be announced on or
about Sept. 25, 1995.

"We are very pleased with our shareholders' receptivity to the distribution of 
Guidant Corporation," said Randall L. Tobias, Lilly chairman and chief executive
officer. "The separation of Lilly and Guidant allows both companies to better 
focus their resources and enhance their competitive positions while maximizing 
shareholder value."

 
Certificates for shares of Guidant Common Stock, checks in lieu of fractional 
Guidant shares, and Lilly shares tendered but not accepted for exchange will be 
mailed on or about Oct. 2, 1995 as designated by the tendering shareholder.

Lilly commenced the Exchange Offer on Aug. 21, 1995, and offered to exchange 
3.49 shares of Guidant Common Stock for each share of Lilly Common Stock 
tendered, up to a maximum of 16,504,298 Lilly shares, resulting in 80.2 percent 
of the outstanding Guidant Common Stock being distributed pursuant to the 
Exchange Offer. Following the exchange, Lilly will have reduced its outstanding 
shares by approximately 5.7 percent and will have approximately 272.8 million
shares of Common Stock outstanding for financial reporting purposes. The 
transaction completes the divestiture of Guidant from Lilly's core
pharmaceutical business.

Lilly is a global research-based pharmaceutical corporation headquartered in 
Indianapolis, Ind., that is dedicated to creating and delivering superior health
care solutions--by combining pharmaceutical innovation, existing pharmaceutical 
technology, disease prevention and management and information technologies--in 
order to provide customers worldwide with optimal clinical and economic 
outcomes.

A leader in the medical device industry, Guidant Corporation provides
innovative, cost-effective products and services to the global cardiology and
minimally invasive surgery marketplaces. Guidant comprises Advanced
Cardiovascular Systems, Inc. (ACS), Cardiac Pacemakers, Inc. (CPI), Devices for
Vascular Intervention, Inc. (DVI), Heart Rhythm Technologies Incorporated (HRT),
Origin Medsystems, Inc. and its international affiliates.

                                   #   #   #

 
                                                                 EXHIBIT (a)(14)



            LILLY AND GUIDANT ANNOUNCE REVISED PRORATION FACTOR FOR
                            GUIDANT EXCHANGE OFFER


Eli Lilly and Company (NYSE:LLY) and Guidant Corporation (NYSE:GDT) announced 
that the preliminary proration factor for the Guidant Exchange Offer should be 
approximately 33.6 percent, rather than 35.5 percent as announced earlier this 
morning.

Lilly is a global research-based pharmaceutical corporation headquartered in 
Indianapolis, Ind., that is dedicated to creating and delivering superior health
care solutions--by combining pharmaceutical innovation, existing pharmaceutical 
technology, disease prevention and management, and information technologies--in 
order to provide customers worldwide with optimal clinical and economic 
outcomes.

A leader in the medical device industry, Guidant Corporation provides 
innovative, cost-effective products and services to the global cardiology and 
minimally invasive surgery marketplaces.  Guidant comprises Advanced 
Cardiovascular Systems, Inc. (ACS), Cardiac Pacemakers, Inc. (CPI), Devices for 
Vascular Intervention, Inc. (DVI), Heart Rhythm Technologies Incorporated (HRT),
Origin Medsystems, Inc. and its international affiliates.

                                  #    #    #